Skip to main content

Advertisement

SpringerLink
Log in

Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

KRAS/BRAF mutation testing and mismatch repair (MMR) protein immunohistochemistry have an established role in routine diagnostic evaluation of colorectal carcinoma (CRC). However, since the exact impact of these molecular characteristics on tumor morphology and behavior is still subject to research, the aim of our study was to examine associations between molecular and morphologic features that had not been analyzed in this combination before. KRAS (codons 12, 13, and 61) and BRAF (codon 600) mutation status and MMR protein expression were analyzed in a consecutive series of 117 CRC samples using DNA pyrosequencing and immunohistochemistry. Tumor cell budding, infiltration pattern, and peritumoral lymphocytic (PTL) reaction was assessed applying established criteria. Molecular and morphological findings were correlated applying chi-square and Fisher’s exact test. We found KRAS or BRAF mutations in 40 and 8 % of samples, while loss of MMR protein expression was observed in 11 %. Tumor budding was significantly associated with infiltrative growth, absence of PTLs, and blood and lymph vessel infiltration. Neither KRAS nor BRAF mutations were associated with a certain growth pattern or budding intensity of CRC, but loss of MMR protein expression was found in context with BRAF mutation, expanding growth, and presence of PTLs. Our results confirm an association between loss of MMR protein expression, presence of activating BRAF mutation, expanding growth, and PTL reaction as well as between tumor budding, infiltrative growth pattern, and tumor aggressiveness; however, there was no such association between the presence of an activating KRAS or BRAF mutation and a distinct invasion pattern or tumor aggressiveness in CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, Mangone L, Francisci S (2012) Progress in colorectal cancer survival in Europe from the late 1980s to the early 21st century: the EUROCARE study. Int J Cancer 131(7):1649–1658. doi:10.1002/ijc.26192

    Article  CAS  PubMed  Google Scholar 

  2. Jass JR, Love SB, Northover JM (1987) A new prognostic classification of rectal cancer. Lancet 1(8545):1303–1306

    Article  CAS  PubMed  Google Scholar 

  3. Jass JR, Ajioka Y, Allen JP, Chan YF, Cohen RJ, Nixon JM, Radojkovic M, Restall AP, Stables SR, Zwi LJ (1996) Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28(6):543–548

    Article  CAS  PubMed  Google Scholar 

  4. Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, Wolf P, Chenard-Neu MP, Jaeck D (2001) Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 182(1):81–88

    Article  CAS  PubMed  Google Scholar 

  5. Yano H, Saito Y, Kirihara Y, Takashima J (2006) Tumor invasion of lymph node capsules in patients with Dukes C colorectal adenocarcinoma. Dis Colon Rectum 49(12):1867–1877. doi:10.1007/s10350-006-0733-9

    Article  PubMed  Google Scholar 

  6. Garcia-Solano J, Conesa-Zamora P, Trujillo-Santos J, Makinen MJ, Perez-Guillermo M (2011) Tumour budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma. Histopathology 59(6):1046–1056. doi:10.1111/j.1365-2559.2011.04043.x

    Article  PubMed  Google Scholar 

  7. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M (1989) An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 63(3):539–543

    Article  CAS  PubMed  Google Scholar 

  8. Hase K, Shatney C, Johnson D, Trollope M, Vierra M (1993) Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 36(7):627–635

    Article  CAS  PubMed  Google Scholar 

  9. Zlobec I, Lugli A (2010) Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 1(7):651–661

    PubMed Central  PubMed  Google Scholar 

  10. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC (2002) Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40(2):127–132

    Article  CAS  PubMed  Google Scholar 

  11. Zlobec I, Lugli A (2009) Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol 15(47):5898–5906

    Article  PubMed Central  PubMed  Google Scholar 

  12. Arnold D, Seufferlein T (2010) Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut 59(6):838–858. doi:10.1136/gut.2009.196006

    Article  CAS  PubMed  Google Scholar 

  13. Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, Novakovic S, Ocvirk J (2011) Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer—a single institution retrospective analysis. Radiol Oncol 45(4):285–291. doi:10.2478/v10019-011-0039-y

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104(5):856–862. doi:10.1038/bjc.2011.19

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, Kim C, Taniyama Y, Kim SI, Choi HJ, Blackmon NL, Lipchik C, Petrelli NJ, O'Connell MJ, Wolmark N, Paik S, Pogue-Geile KL (2012) Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18(23):6531–6541. doi:10.1158/1078-0432. CCR-12-0605

    Article  CAS  PubMed  Google Scholar 

  16. Adackapara CA, Sholl LM, Barletta JA, Hornick JL (2013) Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology 63(2):187–193. doi:10.1111/his.12154

    Article  PubMed  Google Scholar 

  17. de la Chapelle A (2003) Microsatellite instability. N Engl J Med 349(3):209–210. doi:10.1056/NEJMp038099

    Article  PubMed  Google Scholar 

  18. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23(3):609–618. doi:10.1200/JCO.2005.01.086

    Article  CAS  PubMed  Google Scholar 

  19. Makrodouli E, Oikonomou E, Koc M, Andera L, Sasazuki T, Shirasawa S, Pintzas A (2011) BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer 10:118. doi:10.1186/1476-4598-10-118

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Sunaga N, Kaira K, Imai H, Shimizu K, Nakano T, Shames DS, Girard L, Soh J, Sato M, Iwasaki Y, Ishizuka T, Gazdar AF, Minna JD, Mori M (2012) Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene. doi:10.1038/onc.2012.402

    PubMed  Google Scholar 

  21. Wang Z, Ali S, Banerjee S, Bao B, Li Y, Azmi AS, Korc M, Sarkar FH (2013) Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol 228(3):556–562. doi:10.1002/jcp.24162

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Steinestel K, Bruderlein S, Steinestel J, Markl B, Schwerer MJ, Arndt A, Kraft K, Propper C, Moller P (2012) Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis. PLoS One 7(7):e40671. doi:10.1371/journal.pone.0040671

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Gunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, Robert M, Kenney B (2013) KRAS mutations are associated with specific morphologic features in colon cancer. J Clin Gastroenterol 47(6):509–514. doi:10.1097/MCG.0b013e3182703030

    Article  CAS  PubMed  Google Scholar 

  24. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A (2010) Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 127(2):367–380. doi:10.1002/ijc.25042

    CAS  PubMed  Google Scholar 

  25. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S (2012) Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 19(6):1944–1953. doi:10.1245/s10434-011-2174-5

    Article  PubMed Central  PubMed  Google Scholar 

  26. Er TK, Chen CC, Bujanda L, Herreros-Villanueva M (2013) Clinical relevance of KRAS mutations in codon 13: where are we? Cancer Lett. doi:10.1016/j.canlet.2013.09.012

    PubMed  Google Scholar 

  27. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J (2013) Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 31(6):759–765. doi:10.1200/JCO.2012.45.1492

    Article  CAS  PubMed  Google Scholar 

  28. Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A (2012) The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology 61(5):777–787. doi:10.1111/j.1365-2559.2012.04273.x

    Article  PubMed  Google Scholar 

  29. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B (2012) BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 36(5):744–752. doi:10.1097/PAS.0b013e31824430d7

    Article  PubMed  Google Scholar 

  30. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R (2012) Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol 25(10):1315–1325

    Article  CAS  PubMed  Google Scholar 

  31. Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, Castagnola P, Giaretti W (2006) KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Cell Oncol 28(4):161–166

    CAS  PubMed  Google Scholar 

  32. Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer 50(5):307–312. doi:10.1002/gcc.20854

    Article  CAS  PubMed  Google Scholar 

  33. Kloor M, Michel S, von Knebel Doeberitz M (2010) Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 127(5):1001–1010. doi:10.1002/ijc.25283

    Article  CAS  PubMed  Google Scholar 

  34. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR (2012) Prognostic impact of BRAF and KRAS mutations and their relationship to DNA mismatch repair (MMR) status in 2,686 stage III colon cancer patients (pts) treated in a phase III study of adjuvant FOLFOX with or without cetuximab: NCCTG N0147. In: J Clin Oncol (Meeting Abstracts) p 3514

  35. Betge J, Pollheimer MJ, Lindtner RA, Kornprat P, Schlemmer A, Rehak P, Vieth M, Hoefler G, Langner C (2012) Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 118(3):628–638. doi:10.1002/cncr.26310

    Article  PubMed  Google Scholar 

  36. Kojima M, Shimazaki H, Iwaya K, Kage M, Akiba J, Ohkura Y, Horiguchi S, Shomori K, Kushima R, Ajioka Y, Nomura S, Ochiai A (2013) Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer: a framework for developing an objective pathological diagnostic system using the Delphi method, from the Pathology Working Group of the Japanese Society for Cancer of the Colon and Rectum. J Clin Pathol 66(7):551–558. doi:10.1136/jclinpath-2012-201076

    Article  PubMed Central  PubMed  Google Scholar 

  37. Yamauchi H, Togashi K, Kawamura YJ, Horie H, Sasaki J, Tsujinaka S, Yasuda Y, Konishi F (2008) Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today 38(10):905–910

    Article  PubMed  Google Scholar 

  38. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN (2006) Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol 101(12):2818–2825

    Article  CAS  PubMed  Google Scholar 

  39. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB (2012) Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 49(3):151–157. doi:10.1136/jmedgenet-2011-100714

    Article  CAS  PubMed  Google Scholar 

  40. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5:2. doi:10.1186/1476-4598-5-2

    Article  PubMed  Google Scholar 

  41. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S (2010) Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222(4):350–366. doi:10.1002/path.2774

    Article  PubMed Central  PubMed  Google Scholar 

  42. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28(3):466–474

    Article  CAS  PubMed  Google Scholar 

  43. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS (2012) Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from Intergroup Trial CALGB 89803. Clin Cancer Res 18(3):890–900. doi:10.1158/1078-0432.ccr-11-2246

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi M (2013) Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer 13(1):439

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest statement

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Bundeswehr Institute of Radiobiology, Neuherbergstrasse 11, 80937, Munich, Germany

    Konrad Steinestel & Stefan Eder

  2. Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081, Ulm, Germany

    Konrad Steinestel, Klaus Kraft & Annette Arndt

  3. Institute of Pathology, University of Ulm, Albert-Einstein-Allee 23, 89070, Ulm, Germany

    Jochen K. Lennerz

Authors
  1. Konrad Steinestel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jochen K. Lennerz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Eder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Klaus Kraft
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Annette Arndt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konrad Steinestel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steinestel, K., Lennerz, J.K., Eder, S. et al. Invasion pattern and histologic features of tumor aggressiveness correlate with MMR protein expression, but are independent of activating KRAS and BRAF mutations in CRC. Virchows Arch 465, 155–163 (2014). https://doi.org/10.1007/s00428-014-1604-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-014-1604-8

Keywords

Search

Navigation